riccardin-d has been researched along with Liver-Neoplasms* in 1 studies
1 other study(ies) available for riccardin-d and Liver-Neoplasms
| Article | Year |
|---|---|
Riccardin D-26, a synthesized macrocyclic bisbibenzyl compound, inhibits human hepatocellular carcinoma growth through induction of apoptosis in p53-dependent way.
Riccardin D-26 is a synthesized macrocyclic bisbibenzyl compound. We investigated the effect of Riccardin D-26 on human hepatocellular carcinomas. Riccardin D-26 possessed stronger activity against SMMC-7721 cells than human normal liver cells. Riccardin D-26 injection effectively delayed the growth of SMMC-7721 xenografts in mice without significant toxicity. This effect of Riccardin D-26 was associated with the status of p53 and its targets, bax and p21(Waf1)(/)(Cip1). Riccardin D-26 activated p53 expression and induced cancer cells to apoptosis through the p53-mediated transcription-dependent and -independent pathway. Overall, Riccardin D-26 may inhibit hepatocellular carcinoma growth through induction of apoptosis in p53-dependent pathway. Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Macrocyclic Compounds; Mice; Mice, Inbred BALB C; Phenyl Ethers; Stilbenes; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |